Monday, April 24, 2017

Controlling Elevation of Estradiol, Progesterone May Reduce PMDD Symptoms

Previous studies suggest reproductive steroids play a role in premenstrual dysphoric disorder (PMDD)—a disorder characterized by distressing mood and behavioral symptoms that occur during the luteal phase of the menstrual cycle that disappear shortly after menses begin. It is unclear, however, whether these symptoms are triggered by the rapid rise in hormone levels at the start of this phase or the sustained exposure to elevated hormone levels.

A recent study in AJP in Advance suggests that the changes in estradiol and progesterone levels from low to high trigger the onset of PMDD symptoms. 

“Although the mechanisms underlying the mood-destabilizing effects of ovarian steroids in PMDD remain to be better characterized, as does the source of susceptibility to this trigger, our findings provide a new target for interventions,” Peter Schmidt, M.D., chief of the Section on Behavioral Endocrinology at the National Institute of Mental Health, and colleagues reported.

This discovery came from an assessment of 22 women with PMDD, aged 30 to 50, who were given monthly injections of leuprolide to suppress the production of ovarian hormones. Following two to three months of leuprolide alone, 12 of 22 women reported PMDD symptom remission (as determined by self-reported improvement confirmed by Rating for Premenstrual Tension scale scores <5 and the absence of symptom cyclicity on the Daily Rating Form). Women who responded to leuprolide then received one month of placebo followed by three months of estradiol/progesterone replacement therapy.

The women receiving estradiol/progesterone reported a rise in some PMDD symptoms during the first month of therapy, but there were no significant differences in symptom severity during the subsequent months when plasma levels of these sex hormones were stable, Schmidt and colleagues reported.

“[O]ur findings suggest that there is a ‘half-life’ of the affective state that is triggered, following which it remits,” Schmidt and colleagues wrote. “[T]reatment strategies to attenuate or eliminate the change in estradiol and progesterone (or their metabolites) could effectively target the hormonal trigger in this condition.”

For related information, see the Psychiatric News article “Researchers Uncover Cellular Pathway That May Contribute to PMDD.”

(Image: pio3/Shutterstock)


The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising in this newspaper. Clinical opinions are not peer reviewed and thus should be independently verified.